|
| Status |
Public on Jan 23, 2015 |
| Title |
DU145 xenograft in NOD/SCID mice_NVP-BEZ235 and taxotere_4 weeks |
| Sample type |
RNA |
| |
|
| Source name |
DU145 xenograft in NOD/SCID mice_NVP-BEZ235 and taxotere_4 weeks
|
| Organism |
Homo sapiens |
| Characteristics |
cell type: DU145 xenograft in NOD/SCID mice
dose: 10 mg/kg, intravenous for taxotere, 12.5 mg/kg perorally for NVP_BEZ235
schedule: once per week for taxotere and once per day for NVP_BEZ235
|
| Growth protocol |
DU145 xenograft tumors were established by using early-passage cells and maintained in NOD.CB17-Prkdc(SCID) mice. For s.c. tumor development, 100 μL of collagen-embedded cells was injected s.c. into 5- to 8-week-old NOD.CB17-Prkdc(SCID) mice. The mice were observed for 3–5 months for appearance and development of tumors.
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Qiagen RNeasy extraction of total RNA was performed according to the manufacturer's instructions.
|
| Label |
biotin
|
| Label protocol |
Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 500 ng total RNA (Affymetrix GeneChip Expression Manual 701021 Rev.5)
|
| |
|
| Hybridization protocol |
Following fragmentation, 12.5 ug of cRNA were hybridized for 16 hr at 45C on HG_U133_2 Arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 450.
|
| Scan protocol |
GeneChips were scanned using the Affymetrix GeneChip Scanner 3000
|
| Data processing |
CEL files were processed using GCRMA in R (version 2.6.2 (2008-02-08)), using packages downloaded from Bioconductor
|
| |
|
| Submission date |
Jul 25, 2013 |
| Last update date |
Jan 24, 2015 |
| Contact name |
John R Walker |
| E-mail(s) |
[email protected]
|
| Phone |
858-812-1636
|
| Organization name |
Genomics Institute of the Novartis Research Foundation
|
| Lab |
Genetics Core
|
| Street address |
10675 John Jay Hopkins
|
| City |
San Diego |
| State/province |
CA |
| ZIP/Postal code |
92121 |
| Country |
USA |
| |
|
| Platform ID |
GPL570 |
| Series (1) |
| GSE49232 |
Gene expression analysis of in vivo-grown tumors treated with compounds that either de-bulk the tumor or target cancer stem cells |
|
